Clinical trial • Phase III • Other
survodutide for Healthy volunteers
Phase III trial of survodutide for Healthy volunteers. 100 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 23-07-2025
- First CTIS Authorization Date
- 02-09-2025
Trial design
Phase III trial across 2 sites in Germany.
- Target Sample Size
- 100
Recruitment
- Planned Sample Size
- 100
- Recruitment Window Months
- 10
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 100
Germany
- Earliest CTIS Part Ii Submission Date
- 19-08-2025
- Latest Decision Or Authorization Date
- 20-10-2025
- Processing Time Days
- 62
- Number Of Sites
- 2
- Number Of Participants
- 100
Sites
- Site Name
- CRS Clinical Research Services Berlin GmbH
- Contact Person Name
- Mares-Elaine Strempler
- Contact Person Email
- Mares-Elaine.Strempler@crs-group.de
- Site Name
- CRS Clinical Research Services Management GmbH
- Contact Person Name
- Thomas Forst
- Contact Person Email
- Thomas.Forst@crs-group.de
Sponsor
Primary sponsor
- Full Name
- Boehringer Ingelheim International GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Contract research organisations
- Name
- CRS Clinical Research Services Berlin GmbH
- Name
- CRS Clinical Research Services Management GmbH
Investigational products
- Investigational Product Name
- survodutide
Related trials
Other published trials that may interest you.